

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jul 2026

### Evaluation of the effect of Ciochorium intibus syrup on clinical and para clinical manifestations of patients with non-alcoholic fatty liver

#### Protocol summary

##### Study aim

Evaluation of the effect of Ciochorium intibus syrup on clinical and para clinical manifestations of patients with non-alcoholic fatty liver

##### Design

This clinical trial is conducted on 100 patients in two groups of 50, including a control group and parallel groups. This study is single-blind and simple randomization is used

##### Settings and conduct

This study is carried out on patients with active fatty liver of grade 2 and higher (high liver enzymes and ultrasound evidence) referring to Qaem and Imam Reza hospitals in Mashhad. These patients have no involvement in active chronic hepatitis, active viral hepatitis, metabolic liver diseases, autoimmune diseases, drug side effects and do not consume alcohol, and are randomly assigned to two groups receiving drug treatment for 2 months.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria : age of over 20 and below 60; higher than 40 alanine aminotransferase and aspartate aminotransferase serum levels; fatty liver with grade 2 and higher; body mass index of over 27 Exclusion criteria : pregnancy and breastfeeding; use of alcohol; previous history of confirmed liver diseases; use of any diet or drug for the treatment of fatty liver within the last 3 months; autoimmune diseases and all types of malignancy

##### Intervention groups

Intervention group: Patients are treated with Ciochorium intibus syrup for two months, receiving 8 cc of the syrup three times a day, half an hour before each meal. Metformin is also given as the common drug. Control group: The control group receives placebo syrup. Metformin is also given as the common drug.

##### Main outcome variables

Changes in fatty liver grade; serum levels of alanine aminotransferase and aspartate aminotransferase

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20181023041431N1**

Registration date: **2019-03-09, 1397/12/18**

Registration timing: **prospective**

Last update: **2019-03-09, 1397/12/18**

Update count: **0**

##### Registration date

2019-03-09, 1397/12/18

##### Registrant information

##### Name

Hossein Ramezani hodk

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 51 3225 4307

##### Email address

ramezanih2@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-03-11, 1397/12/20

##### Expected recruitment end date

2019-06-21, 1398/03/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Evaluation of the effect of Ciochorium intibus syrup on clinical and para clinical manifestations of patients with non-alcoholic fatty liver

**Public title**

Effectiveness of Ciochorium intibus syrup on non-alcoholic fatty liver

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age of over 20 and below 60 Higher than 40 alanine aminotransferase and aspartate aminotransferase serum levels Fatty liver with grade 2 and higher Body mass index of over 27

**Exclusion criteria:**

Pregnancy and breastfeeding Use of alcohol Previous history of confirmed liver diseases Use of any diet or drug for the treatment of fatty liver within the last 3 months Confirmed autoimmune diseases All types of malignancy

**Age**

From **20 years** old to **60 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant

**Sample size**

Target sample size: **100**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization will be based on a random allocation table provided by a computer. In order to conceal the random allocation of the groups, sealed envelopes will be used. Then, the envelopes are opened in sequence for each patient and the method of treatment becomes known.

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

This is a single-blind study in which the participants are unaware of their treatments, and the type of drug treatment is based on sealed envelopes.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1**

Ethics committee

**Name of ethics committee**

Ethics Committee of Mashhad University of Medical Sciences

**Street address**

Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah Street

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9138813944

**Approval date**

2018-04-11, 1397/01/22

**Ethics committee reference number**

IR.MUMS.MEDICAL.REC.1397.704

**Health conditions studied****1****Description of health condition studied**

non-alcoholic fatty liver

**ICD-10 code**

K76.0

**ICD-10 code description**

Fatty (change of) liver, not elsewhere classified

**Primary outcomes****1****Description**

Serum level of alanine aminotransferase

**Timepoint**

At the beginning of the study (before the intervention) and at the end of the intervention

**Method of measurement**

Biochemical tests

**2****Description**

Serum level of aspartate aminotransferase

**Timepoint**

At the beginning of the study (before the intervention) and at the end of the intervention

**Method of measurement**

Biochemical tests

**3****Description**

Change in fatty liver grade

**Timepoint**

Before and after intervention

**Method of measurement**

Sonography

**Secondary outcomes**

empty

## Intervention groups

### 1

#### Description

Intervention group: Patients are treated with Clochorium intibus syrup for two months, receiving 8 cc of the syrup three times a day, half an hour before each meal. Metformin is also given as the common drug.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: The control group receives placebo syrup. Metformin is also given as the common drug.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Ghaem hospital

##### Full name of responsible person

Dr Seyed Mousareza Hoseinin

##### Street address

Ghaem hospital, Ahmad Abad Ave

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9176699199

##### Phone

+98 51 3801 2742

##### Email

HoseiniMR@mums.ac.ir

### 2

#### Recruitment center

##### Name of recruitment center

Imam Reza Hospital

##### Full name of responsible person

Hosseini Ramezani

##### Street address

Imam Reza Hospital, Imam Reza square, Ebn\_e\_sina Avenue

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9137913316

##### Phone

+98 51 3802 2769

##### Email

ramezanihh@mums.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Dr Mohsen Tafaghodi

##### Street address

Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah street

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9138813944

##### Phone

+98 51 3841 2081

##### Email

ramresearch@mums.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Mashhad University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Dr Seyed Mousareza Hoseini

##### Position

Assistant professor

##### Latest degree

Subspecialist

##### Other areas of specialty/work

Internal Medicine

##### Street address

Ghaem Hospital, Ahmad Abad Avenue

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9176699199

**Phone**  
+98 51 3801 2742  
**Email**  
hoseinimr@mums.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Mashhad University of Medical Sciences  
**Full name of responsible person**  
Dr Seyed Mousareza Hoseinin  
**Position**  
Assistant professor  
**Latest degree**  
Subspecialist  
**Other areas of specialty/work**  
Internal Medicine  
**Street address**  
Ghaem Hospital, Ahmad Abad Avenue  
**City**  
Mashhad  
**Province**  
Razavi Khorasan  
**Postal code**  
9176699199  
**Phone**  
+98 51 3801 2742  
**Email**  
HoseiniMR@mums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Mashhad University of Medical Sciences  
**Full name of responsible person**  
Hosein Ramezani  
**Position**  
Resident  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Internal Medicine  
**Street address**  
Imam Reza Hospital, Imam Reza square, Ebn\_e\_sina

Avenue  
**City**  
Mashhad  
**Province**  
Razavi Khorasan  
**Postal code**  
9137913316  
**Phone**  
+98 51 3802 2769  
**Email**  
ramezanihh@mums.ac.ir

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Not applicable

### Data Dictionary

Not applicable

### Title and more details about the data/document

All data can be shared after patients are made unidentifiable.

### When the data will become available and for how long

Data can be accessible 6 months after results are published.

### To whom data/document is available

Data will be available for researchers in universities and other scientific institutes.

### Under which criteria data/document could be used

Carrying out analysis on data is permitted.

### From where data/document is obtainable

Data can be accessible through sending an email to the corresponding author.

### What processes are involved for a request to access data/document

After sending a request email to the corresponding author, data will be sent in 1 month.

### Comments